Metsera's MET-233i Shows 8.4% Weight Loss in Phase 1MetseraMetsera reports positive Phase 1 results for MET-233i, its once-monthly amylin analog, showing up to 8.4% weight loss and strong tolerability. Combination trials with GLP-1 therapy underway.
Weight Loss Medications and Safety ConcernsWeight loss drugsExplore the rise and fall of weight loss medications like Fenfluramine, Sibutramine, and more. Learn about the dangers, side effects, and FDA withdrawals of these drugs throughout history.
Pfizer CEO: All-in on Weight Loss Drug DevelopmentPfizerPfizer CEO Albert Bourla focuses on advancing weight loss drug development, with new small molecule GLP-1 treatments and cancer therapies. The company aims to tackle challenges in a rapidly growing market.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
